Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Cash & Current Investments (2016 - 2025)

UroGen Pharma's Cash & Current Investments history spans 10 years, with the latest figure at $112.1 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments fell 35.23% year-over-year to $112.1 million; the TTM value through Dec 2025 reached $112.1 million, down 35.23%, while the annual FY2025 figure was $112.1 million, 35.23% down from the prior year.
  • Cash & Current Investments reached $112.1 million in Q4 2025 per URGN's latest filing, down from $127.0 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $249.6 million in Q3 2024 to a low of $811000.0 in Q2 2022.
  • Average Cash & Current Investments over 5 years is $113.5 million, with a median of $109.2 million recorded in 2021.
  • Peak YoY movement for Cash & Current Investments: plummeted 98.74% in 2022, then soared 2482.37% in 2023.
  • A 5-year view of Cash & Current Investments shows it stood at $45.6 million in 2021, then skyrocketed by 119.29% to $100.0 million in 2022, then skyrocketed by 37.02% to $137.0 million in 2023, then increased by 26.35% to $173.1 million in 2024, then tumbled by 35.23% to $112.1 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Cash & Current Investments are $112.1 million (Q4 2025), $127.0 million (Q3 2025), and $157.0 million (Q2 2025).